

Adam Martidis, M.D.

Retina Consultants of Southern Colorado, P.C.
2770 North Union Blvd., Suite 140
Colorado Springs, CO 80909
719-473-9595

CURRENT POSITION

2020 – Present Retina Consultants of Southern Colorado, P.C.
Colorado Springs, CO

EMPLOYMENT HISTORY

2009-2020 Limberg Eye Surgery
San Luis Obispo, CA

2008-2020 Miramar Eye Specialists
Ventura, CA

2005-2008 Retina Institute of California
Pasadena, CA

2001-2005 Wills Eye Hospital, Associated Retinal Consultants
Thomas Jefferson University
Philadelphia, PA

EDUCATION

1999-2001 Fellowship, Vitreoretinal Diseases
New England Eye Center, Tufts University
Boston, MA

1996-1999 Residency, Ophthalmology (Chief Resident 1999)
Indiana University School of Medicine
Indianapolis, IN

1995-1996 Internship, Transitional Medicine
Mercy Hospital of Pittsburgh
Pittsburgh, PA

1991-1995 M.D., University of Pittsburgh School of Medicine
Pittsburgh, PA

1986-1990 B.S., Duke University School of Engineering
Durham, NC
Majors: Biomedical & Electrical Engineering

Adam Martidis, M.D.

SPECIALTY CERTIFICATIONS

2011	Recertification, Diplomate, American Board of Ophthalmology
2001	Certification, Diplomate, American Board of Ophthalmology

MEDICAL LICENSURE

2020-present	Colorado (DR0063668)
2006-present	California (A95007)
2001-present	DEA (BM6329165)
2005	Georgia (055839)
2001-2005	Pennsylvania (MD072745L)
2001-2005	New Jersey (MA072542)

HONORS & AWARDS

2008	Achievement Award, <i>American Academy of Ophthalmology</i>
2008	America's Top Doctors, Ophthalmology
2008	Top Doctor, Ophthalmology; <i>Pasadena Magazine</i>
1998-1999	Chief Administrative Resident, Indiana University Dept. of Ophthalmology
1999	Grayson Leadership Award, Indiana University Dept. of Ophthalmology
1999	<i>Best Research Paper</i> ; Residents' Research Day
1993	Award for Excellence in Research, University of Pittsburgh School of Med
1986	Distinguished Scholar; NJ Dept. of Higher Education

HOSPITAL PRIVILEGES

2008-present	Los Robles Hospital Thousand Oaks, CA
2006-2008	Huntington Medical Center Pasadena, CA
2001-2005	Wills Eye Hospital Philadelphia, PA

LICENSURE

Current	Colorado, California
Inactive licenses	New Jersey, Pennsylvania, Georgia

PROFESSIONAL SOCIETIES

2006- present	Retina Society
1999- present	American Society of Retina Specialists
1996- present	American Academy of Ophthalmology

Adam Martidis, M.D.

CLINICAL RESEARCH

Principal Investigator:

RegenXBio RGX-314 (Atmosphere)

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

Fast Track/60° Pharmaceuticals 60PH04 (Tafenoquine)

Multisite, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine

Lpath, Inc. iSONEP (Nexus)

Phase 2a, Multicenter, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis/Avastin/Eylea Versus Lucentis/Avastin/Eylea Alone for Treatment of Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Genentech FVF4579g (Harbor)

A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

Neovista (Cabernet)

A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration

Ophthotech OPH1004 (Solaris)

A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (Anti-PDGF-B Pegylated Aptamer) Administered in combination with Either Avastin or Eylea Compared to Avastin or Eylea Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration

Opko Health, Inc. (Cobalt)

A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).

Genentech (Marina)

Anti-VEGF agent rhuFab for minimally classic choroidal neovascularization

Adam Martidis, M.D.

Genentech (Anchor)

A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared with Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration

Immusol Vitrenase 63756

Ribozyme for prevention of proliferative vitreoretinopathy.

National Institute of Health/National Eye Institute (SCORE)

Advisory Committee Member

Intravitreal Triamcinolone for Retinal Vein Occlusion

Diabetic Retinopathy Collaborative Network

Advisory Committee Member

Intravitreal Triamcinolone for Diabetic Macular Edema

Co-Investigator:

Genentech (Bravo)

A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion

Genentech (Cruise)

A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion

Genentech (Ride)

Ranibizumab for macular edema due to diabetic retinopathy

Wilmer Eye Institute (Read)

Ranibizumab for macular edema due to diabetic retinopathy

VisionCare Ophthalmic Technologies Inc. IMT-002

Five Year Follow-up of IMT-002 Patients; A Long-Term Monitoring Study of IMT-002 Patients

QLT Phototherapeutics (VIO)

A Randomized, Placebo-Controlled, Double-Masked, Multicenter, Phase III Study of the Effect of Visudyne Therapy in Occult With No Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Visudyne in Occult (VIO)

Iridex Iris Medical TTT4CNV

Transpupillary thermotherapy for occult subfoveal choroidal neovascularization.

Adam Martidis, M.D.

Sub-Investigator:

Alimera Sciences, Inc 01-20-005 (Alimera)

A randomized, masked, controlled study of intravitreal Iluvien implant as baseline therapy in patients with early diabetic macular edema (DME)

Bayer AG US: Regeneron Pharmaceuticals, Inc. BAY 86-5321 (Pulsar)

Randomized, double-masked, active-controlled, phase 3 study of the efficacy and safety of high dose aflibercept in patients with neovascular age-related macular degeneration

Chengdu Kanghong KHB-1802 (Panda)

A Multicenter, Double-masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration

Clover Therapeutics (Clover)

For Age-related Macular Degeneration disease history and progression for nonexudative age-related macular degeneration with intermediate dry stage, advanced atrophic without subfoveal involvement, or advanced atrophic with subfoveal involvement

EyePoint Pharmaceuticals, Inc. EYP-YUT-0001 (Calm)

A Retrospective Registry Study to Collect Real-world Data on YUTIQ, a Fluocinolone Acetonide Intravitreal Implant, for the Treatment of Chronic

Genentech/Roche GR40398 (Rhine)

A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema

Genentech/Roche GR40306 (Tenaya)

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab In Patients With Neovascular Age-Related Macular Degeneration

Iveric Bio, Inc. ISEE2008 (Iveric)

A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

MacTel NHOR Registry

A Natural History Observation and Registry Study of Macular Telangiectasia Type 2

Miravant Technologies Miravant SnET2 PDT

Purlytin photodynamic therapy for subfoveal choroidal neovascularization.

Adam Martidis, M.D.

NGM – Bio NGM621-GA-201 (Catalina)

A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Novartis CRTH258B2301 (Kestrel)

A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema

Novartis CRTH258AUS04 (Merlin)

A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg q4 weeks compared to aflibercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid

Novartis CRTH258C2301 (Raptor)

An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion

Novartis CRTH258C2302 (Raven)

An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion

Opthea OPT-302-1004

Phase 3 study of OPT-302 with ranibizumab in neovascular AMD QLT Phototherapeutics (VAM)
Verteporfin photodynamic therapy for subfoveal choroidal neovascularization.

Regeneron VGFTE-HD-DME-1934 (Photon)

A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema

Regeneron AMD-1905 (Candela) A randomized, single-masked, active-controlled phase 2 study of the safety, tolerability, and efficacy of repeated doses of high-dose aflibercept in patients with neovascular age-related macular degeneration

Adam Martidis, M.D.

Roche GR41987 (Rhone-X)

A multicenter, open label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with diabetic macular edema (Rhone/Rhine Extension)

Roche GR40973 (GAllego)

A phase II, multicenter, randomized, single-masked, sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of FHTR2163 in patients with Geographic Atrophy secondary to age-related macular degeneration

Roche GR42691 (Avonelle-X)

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration

Roche NPDR CB1 phase II- MJ (Canberra)

A randomized, double-masked, 48-week, parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of rg7774 in patients with diabetes mellitus type 1 or type 2 with treatment-naïve diabetic retinopathy

Samsung SB15-3001-AMD

A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB15 (proposed aflibercept biosimilar) and Eylea in Subjects with Neovascular Age-related Macular Degeneration

EDITORIAL POSITIONS/COMMITTEES/CONSULTANCIES:

2012 -2017	Genentech Advisory Board
2016-2017	Consultant, TrueVision, Inc
2005-2017	Lecturer, Genentech, Inc
2016	Retina Advisory Committee (RAC), Alcon, Inc
2006-2014	Basic Clinical & Science Course Committee American Academy of Ophthalmology
2006-2009	Section Editor, “Cutting Through the Vitreous” <i>Retina Times</i> , Official Publication, American Society of Retina Specialists
2005-2008	Consultant, iScience, Inc
2001	Retina Module Editor OPHTHALMIC hyperguide™ , Slack, Inc.

Adam Martidis, M.D.

ACADEMIC APPOINTMENTS:

- 2003-2005 Assistant Professor of Ophthalmology
Thomas Jefferson University, *Philadelphia, PA*
- 2003 Assistant Surgeon, Retina Service
Director, Ultrasonography/Optical Coherence Tomography
Wills Eye Hospital, *Philadelphia, PA*

INVITED LECTURES:

1. “Age-related macular degeneration.”
Genentech Genie, *Omaha, NE*, August 4, 2016.
2. “NGenuity in vitreoretinal surgery.”
TrueVision, *Santa Barbara CA*, June 7, 2016.
3. “Anti-VEGF therapy in retinal diseases.”
Genentech Genie, *New Orleans, LA*, June 18, 2015.
4. “Anti-VEGF therapy in retinal diseases.”
Genentech Genie, *Shreveport, LA*, June 17, 2015.
5. “Diabetic retinopathy & retinal vein occlusion.”
Genentech Genie, *Las Vegas, NV*, October 30, 2014.
6. “Current perspectives in retinal diseases.”
Advisory Panel, *Los Angeles, CA*, October 15, 2014
7. “Diabetic retinopathy.”
Genentech Genie, *Seattle WA*, March 11, 2014.
8. “Age-related macular degeneration & retinal vein occlusion.”
Genentech Genie, *Elko, NV*, July 22, 2014.
9. “Diabetic retinopathy & retinal vein occlusion.”
Genentech Genie, *Jackson, MS*, March 14, 2012.
10. “Age-related macular degeneration & retinal vein occlusion.”
Genentech Genie, *Lafayette, LA*, May 13, 2013.
11. “Diabetic retinopathy and retinal vein occlusion.”
Genentech Genie, *San Antonio, TX*, April 9, 2013.
12. “Age-related macular degeneration & retinal vein occlusion.”
Genentech Genie, *New Orleans, LA*, January 24, 2013.
13. “Age-related macular degeneration & retinal vein occlusion.”
Genentech Genie, *Hattiesburg, MS*, November 29, 2012.

Adam Martidis, M.D.

14. "Age-related macular degeneration & retinal vein occlusion."
Genentech Genie, *South Bend, IN*, October 24, 2012.
15. "Retinal vein occlusion."
Genentech Genie, *Denver, CO*, September 27, 2012.
16. "Age-related macular degeneration & retinal vein occlusion."
Genentech Genie, *Austin, TX*, September 26 2012.
17. "Age-related macular degeneration & retinal vein occlusion."
Genentech Genie, *San Diego, CA*, September 25, 2012.
18. "Age-related macular degeneration."
University Village, *Thousand Oaks, CA*, March 23, 2012.
19. "Age-related macular degeneration & retinal vein occlusion."
Genentech Genie, *Wichita, KS*, March 14, 2012.
20. "Retinal vein occlusion."
Genentech Genie, *Signal Hill, CA*, November 10, 2011.
21. "Retinal vein occlusion."
Genentech Genie, *La Jolla, CA*, October 13, 2011.
22. "Retinal vein occlusion."
Genentech Genie, *Medford, OR*, August 3, 2011.
23. "Retinal vein occlusion."
Genentech Genie, *San Jose, CA*, April 19, 2011.
24. "Retinal vein occlusion."
Genentech Genie, *Kapolei, HI*, March 2, 2011.
25. "Age-related macular degeneration."
Eye on AMD Seminar, *Colorado Springs, CO*, October 16, 2010.
26. "Age-related macular degeneration."
Eye on AMD Seminar, *San Antonio, TX*, May 15, 2010.
27. "Advances in macular degeneration and diabetic retinopathy."
Tri-County Optometric Society Annual Meeting, *Ventura, CA*, May 8, 2010.
28. "Age-related macular degeneration."
Eye on AMD Seminar, *Indianapolis, IN*, April 23, 2010.
29. "HORIZON trial results."
Genentech Annual Meeting, *Las Vegas, NV*, January 27, 2010.
30. "Latest advances in vitreoretinal diseases."
TLC Update, *Camarillo, CA*, April 30, 2009.

Adam Martidis, M.D.

31. "Age-related macular degeneration."
Eye on AMD Seminar, *Sacramento, CA*, April 25, 2009.
32. "Age-related macular degeneration."
Eye on AMD Seminar, *Mesa, AZ*, March 14, 2009.
33. "Age-related macular degeneration."
Eye on AMD Seminar, *Surprise, AZ*, November 15, 2008.
34. "Advanced in retinal diseases."
Optimist Club, *Pasadena, CA*, October 23, 2008.
35. "Age-related macular degeneration."
Eye on AMD Seminar, *Metairie, LA*, October 18, 2008.
36. "Age-related macular degeneration."
Eye on AMD Seminar, *Denver, CO*, August 22, 2008.
37. "Age-related macular degeneration."
Eye on AMD Seminar, *Nashville, TN*, August, 2008.
38. "Age-related macular degeneration."
Eye on AMD Seminar, *Nashville, TN*, August, 2008.
39. "Age-related macular degeneration."
Eye on AMD Seminar, *Skokie, IL*, October 11, 2007.
40. "Bevacizumab versus ranibizumab for neovascular AMD."
American Society of Retina Specialists Annual Meeting,
Indian Wells, CA, December 1, 2007.
41. "Pars plana vitrectomy: when is bigger better?"
Course Instructor, American Academy of Ophthalmology,
New Orleans, LA, November, 2007.
42. "Bevacizumab versus ranibizumab for neovascular AMD."
Faculty, Retina Subspecialty Day, American Academy of Ophthalmology, *New Orleans, LA*,
November, 2007.
43. "Age-related macular degeneration."
Eye on AMD Seminar, *Skokie, IL*, October 11, 2007
44. "Advances in retinal imaging; spectral domain OCT,"
Eye on 2007 Educational Seminar. *Pasadena, CA*, September 2007.
45. "25 gauge vitrectomy for proliferative vitreoretinopathy"
Vail Vitrectomy Conference, *Vail, CO*, March 11, 2007.
46. "Current management of diabetic retinopathy."
Inland Empire Optometric Society, *Ontario, CA*, March 4, 2007.

Adam Martidis, M.D.

47. "Diabetic retinopathy: where have we been, and where are we going?"
San Gabriel Valley Optometric Society, *Pasadena, CA*, November 8, 2006
48. "Advances in 25-gauge vitrectomy surgery."
Eye on 2006 Educational Seminar. *Pasadena, CA*, August 19, 2006.
49. "OCT for the clinician: an international experience."
Course Instructor; American Academy of Ophthalmology, *Chicago, IL*,
October 16, 2005.
50. "New research in age-related macular degeneration."
Macula Vision Research Foundation, *Atlanta, GA*, June 25, 2005.
51. "Triamcinolone-assisted vitrectomy surgery."
Faculty, Retina Subspecialty Day; American Academy of Ophthalmology, *New Orleans, LA*,
October 22, 2004.
52. "OCT for the clinician: an international experience."
Course Instructor; American Academy of Ophthalmology, *New Orleans, LA*,
October 26, 2004.
53. "Triamcinolone-assisted membrane peeling for proliferative vitreoretinopathy in
pseudophakic retinal detachment." XXIVth Meeting of the Club Jules Gonin. *Athens, Greece*,
September 12, 2004.
54. "Medical and surgical uses of intravitreal triamcinolone."
Visiting Professor, Indiana University Residents' Day, *Indianapolis, IN*, June 25, 2004.
55. "Triamcinolone-assisted membrane peeling for proliferative diabetic retinopathy." Vail
Vitrectomy Conference, *Vail, CO*, April 14, 2004
56. "Anti-neovascular agent, rhuFab (Lucentis), in the management of exudative age-related
macular degeneration." Retina Update, Wills Eye Hospital, *Philadelphia, PA*, February 12,
2004.
57. "Triamcinolone-assisted membrane peeling in diabetic retinopathy and proliferative
vitreoretinopathy." American Society of Retina Specialists. *New York, NY*, August 17, 2003.
58. "Intravitreal Triamcinolone for Diabetic Macular Edema."
Genentech Macular Edema Advisory Committee, *Chicago, IL*, June 2, 2003.
59. "Intravitreal Triamcinolone for Cystoid & Diabetic Macular Edema."
American Society of Cataract & Refractive Surgery, *San Francisco, CA*, April 15, 2003.
60. "Intravitreal triamcinolone: medical and surgical uses."
Advanced Vitreoretinal Course, *Antwerp, Belgium*, April 4, 2003.
61. "Transpupillary thermotherapy: a new treatment paradigm."
Advanced Vitreoretinal Course, *Antwerp, Belgium*, April 4, 2003.
62. "Intravitreal triamcinolone for macular edema."

Adam Martidis, M.D.

- Macula 2003: Atlantic Coast Retina Conference, *New York, NY*, January 18, 2003.
63. "Retina 2003: Diagnostic imaging and therapeutic intervention."
South Jersey Optometric Society, *Buena Vista, NJ*, January 6, 2003.
 64. "Triamcinolone-assisted membrane peeling for proliferative vitreoretinopathy."
Wills Eye Hospital Scientific Symposium, *Philadelphia, PA*, November 2, 2002.
 65. "Intravitreal triamcinolone for refractory diabetic macular edema."
Retina Congress, *San Francisco, CA*, September 30, 2002.
 66. "Sympathetic ophthalmia presenting as multiple evanescent white dot syndrome." Wills Eye Hospital Annual Retina Conference, *Philadelphia, PA*, September 13, 2002.
 67. "New approaches to diabetic retinopathy: diagnostic imaging & therapies."
Black Hills Eye Center Course, *Rapid City, SD*, April 6, 2002.
 68. "Review of vitreoretinal diseases."
Visiting Professor: Bascom Palmer Eye Institute, *Miami, FL*, April 5, 2002.
 69. "Intravitreal corticosteroids for diabetic macular edema."
Wills Eye Hospital Annual Conference, *Bala Cynwyd, PA*, March 21, 2002.
 70. "New strategies for the treatment of diabetic macular edema: intravitreal corticosteroids v. surgery." Wills Eye Hospital Vitreoretinal Update, *Philadelphia, PA*, March 9, 2002.
 71. "Optical Coherence Tomography: clinical correlation."
Wills Eye Hospital Vitreoretinal Update, *Philadelphia, PA*, March 9, 2002.
 72. "Case report: intravitreal triamcinolone for diabetic macular edema."
Atlantic Coast Retina Conference, *Philadelphia, PA*, February 18, 2002.
 73. "Intravitreal triamcinolone acetate for refractory diabetic macular edema."
Wills Eye Hospital Vitreoretinal Update, *Philadelphia, PA*. October 6, 2001.
 74. "Case report: toxemia of pregnancy."
Wills Eye Hospital Retina Club Conference, *Philadelphia, PA*. October 5, 2001
 75. "Intravitreal triamcinolone acetate for refractory diabetic macular edema."
Association for Research in Vision & Ophthalmology, *Ft. Lauderdale, FL*. May 3, 2001.
 76. "Intravitreal triamcinolone acetate for refractory diabetic macular edema."
International Symposium on Optical Coherence Tomography, *Longboat Key, FL*. April 26, 2001.
 77. "Optical coherence tomography in the management of photodynamic therapy." International Symposium on Optical Coherence Tomography, *Longboat Key, FL*. April 27, 2000.
 78. "Ataxia and butterfly MRI."
31st Annual Frank B. Walsh Society Meeting, *Atlanta, GA*. February 6, 1999.

Adam Martidis, M.D.

79. "Ocular histoplasmosis: subfoveal surgery & steroids revisited."
Theodore F. Schlaegel, Jr, MD Lecture, *Indianapolis, IN*. September 26, 1997.
80. "ICG angiography of exudative age-related macular degeneration."
Association for Research in Vision & Ophthalmology, *Ft. Lauderdale, FL*; May 12, 1997.
81. "ICG angiography of exudative age-related macular degeneration."
Indiana Academy of Ophthalmology, *Indianapolis, IN*; June 14, 1997.

BIBLIOGRAPHY

Publications (peer-reviewed)

1. Martidis A, Chang TS. "25 gauge sutureless vitrectomy surgery; risky or rewarding?"
Editorial. *Ophthalmology* 2007.09.003.
2. Weichel ED, Martidis A, Fineman MS, McNamara JA, Park CH, Vander JF, Ho AC, Brown GC. Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachment. *Ophthalmology*. 2006 Nov;113(11):2033-40.
3. Smith BT, Park CH, Federman JL, Sarin LK, Martidis A. Efficient total detachment of the retina for full macular translocation. *Retina*. 2006 May-Jun;26(5):580-3.
4. Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, Fontanarosa J, Moster MR. Intraocular pressure alterations following intravitreal triamcinolone acetonide. *Br J Ophthalmol*. 2006 Aug;90(8):999-1003.
5. Chieh JJ, Roth DB, Liu M, Belmont J, Nelson M, Regillo C, Martidis A. Intravitreal triamcinolone acetonide for diabetic macular edema. *Retina*. 2005 Oct;25(7):828-34.
6. Bauman CR, Martidis A, Truong SN. Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis. *Arch Ophthalmol*. 2004 Jun;122(6):926-8.
7. Garg SJ, Martidis A, Nelson ML, Sivalingam A. Optical coherence tomography of chronic solar retinopathy. *Am J Ophthalmol*. 2004 Feb;137(2):351-4.
8. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. *Retina*. 2003 Oct;23(5):686-91.
9. Borrillo JL, Sivalingam A, Martidis A, Federman JL. Surgical ablation of retinal angiomatous proliferation. *Arch Ophthalmol* 2003;121(4):558-61.
10. Rogers AH, Greenberg PB, Martidis A, Puliafito CA. Photodynamic therapy of polypoidal choroidal vasculopathy. *Ophthalmic Surg Lasers Imaging*. 2003 Jan-Feb;34(1):60-3.
11. Nelson M and Martidis A. Managing cystoid macular edema after cataract surgery. *Curr Opin Ophthalmol* 2003; Feb 14(1):39-43. Review.

Adam Martidis, M.D.

12. Rogers A, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy for choroidal neovascularization. *Am J Ophthalmol* 2002; Oct 134(4):566-76.
13. Chen D, Martidis A, Bauman CR. Transient multifocal electroretinogram dysfunction in multiple evanescent white dot syndrome. *Ophthalmic Surg Lasers* 2002; May-Jun;33(3):246-9.
14. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Bauman C. Intravitreal triamcinolone for refractory diabetic macular edema. *Ophthalmology* 2002 May;109(5):920-7.
15. Martidis A, Danis RP, Ciulla TA. Treating cytomegalovirus retinitis-related retinal detachment by combining silicone oil tamponade and ganciclovir implant. *Ophthalmic Surg Lasers* 2002; Mar-Apr;33(2):135-9.
16. Martidis A, Greenberg PB, Rogers AH, Velazquez-Estades LJ, Bauman CR. Multifocal electroretinography response after laser photocoagulation of a subretinal nematode. *Am J Ophthalmol* 2002 Mar;133(3):417-9.
17. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. *Br J Ophthalmol* 2002; Feb;86(2):247-8.
18. Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. *Arch Ophthalmol* 2001 Sep;119(9):1380-3.
19. Puliafito CA and Martidis A. Verteporfin: A viewpoint by Carmen A. Puliafito and Adam Martidis. *Drugs & Aging* 2000;16(2).
20. Martidis A, Miller DG, Ciulla TA, Danis RP, Moorthy RS. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. *J Ocul Pharmacol Ther* 1999;15(5):425-8.
21. Martidis A, Yee RD, Azzarelli B, Biller J. Neuro-ophthalmic, radiographic, and pathologic manifestations of adult-onset Alexander disease. *Arch Ophthalmol* 1999;117:265-7.
22. Martidis A, Yung CW, Ciulla TA. Talc embolism: a static retinopathy. *Am J Ophthalmol* 1997;124(6):841-3.
23. Ganguli R, Mintun MA, Becker JT, Brar JS, Diehl D, Deleo M, Madoff D, Martidis A. Effects of hydrocortisone infusion on rCBF in schizophrenic patients during a memory task. An O15 PET Study. *Ann N Y Acad Sci.* 1994 Nov 30;746:385-7.

Publications (non peer-reviewed)

1. Martidis A and Duker JS. Subretinal hemorrhage associated with congenital retinal telangiectasis. *Ocular Surgery News*, January 1, 2000;18:1;48,54.
2. Martidis A and Duker JS. Macular edema associated with combined hamartoma of the retina and RPE. *Ocular Surgery News*, April 15, 2000;18:8;110,118.

Adam Martidis, M.D.

3. Martidis A and Reichel E. Choroidal neovascularization due to angioid streaks from pseudoxanthoma elasticum. *Ocular Surgery News*, July 15, 2000;18:14;76,82.
4. Martidis A and Duker JS. *Ocular Surgery News*, November 15, 1999;17:22,69. Book Review: Alfaro DV and Liggett PE (eds). Vitreoretinal Surgery of the Injured Eye. Philadelphia: Lippincott-Raven Publishers; 1999.

Abstracts

1. Martidis A, Danis RP, Ciulla TA, McNulty L. Indocyanine green angiography of exudative age-related macular degeneration. *Invest Ophthalmol Vis Sci* 1997;38:4,S239.
2. Martidis A, Danis RP, Ciulla TA. Treatment of rhegmatogenous retinal detachment due to CMV retinitis with combination pars plana vitrectomy/silicone oil tamponade and sustained-release ganciclovir implant. *Invest Ophthalmol Vis Sci* 1998;39:4,S135.
3. Rivellesse M, Martidis A, Puliafito CA. Evaluation of photodynamic therapy of age-related macular degeneration with optical coherence tomography. *Vitreous Society*, 1999.
4. Martidis A, Rivellesse M, Puliafito CA. Optical coherence tomography evaluation of macular thickness after photodynamic therapy with verteporfin. *Invest Ophthalmol Vis Sci* 2000;41:4,S177.
5. Rivellesse M, Martidis A, Prien J, Lederer D, Puliafito CA. Volumetric quantification of macular edema using optical coherence tomography. *Invest Ophthalmol Vis Sci* 2000;41:4,S951.
6. Glavas IP, Martidis A, Rivellesse M, Reichel E, Puliafito CA. Treatment of subfoveal choroidal neovascularization with intravitreal triamcinolone acetate. *Invest Ophthalmol Vis Sci* 2000;41:4,S320.
7. Martidis A, Rogers A, Greenberg PB, Duker JS, Reichel E, Puliafito CA. Intravitreal triamcinolone for refractory diabetic macular edema. *Invest Ophthalmol Vis Sci* 2001; 42:4,S741.
8. Puliafito CA, Martidis A, Rogers A, Greenberg PB. An OCT classification system for choroidal neovascularization treated with photodynamic therapy. *Macula Society*, 2001.
9. Rogers A, Martidis A, Greenberg PB, Truong SN, Puliafito CA. Optical coherence tomography of subfoveal choroidal neovascularization treated with photodynamic therapy. *Invest Ophthalmol Vis Sci* 2001; 42:4,S512.
10. Greenberg PB, Rogers A, Martidis A, Duker JS, Puliafito CA. Photodynamic therapy with verteporfin for choroidal neovascularization due to angioid streaks. *Invest Ophthalmol Vis Sci* 2001; 42:4,S440.
11. Tennant MT, Shuler M, Martidis A, Belmont JB. Photodynamic therapy in multifocal choroiditis. *Invest Ophthalmol Vis Sci* 2002;

Adam Martidis, M.D.

12. Zhao J, Maust HA, Tennant MT, Martidis A, Vrabec TR. Optical coherence tomography, electroretinography, multifocal ERG, intravenous fluorescein angiography, and clinical findings in two cases of familial Bietti's crystalline dystrophy. *Invest Ophthalmol Vis Sci* 2002;
13. Federman JL, Martidis A, Nelson ML, Belmont JB, Sivalingam A, Miller DG. Intravitreal triamcinolone for refractory diabetic macular edema. *Macula Society* 2002.
14. Martidis A, Nelson ML, Baker B, Duker JS, Reichel E, Rogers AH, Federman JL, Sivalingam A, Belmont JB, Miller DG. Intravitreal triamcinolone for refractory diabetic macular edema. *Retina Congress* 2002.
15. Blade KA, Martidis A, Nelson ML, Belmont JB, Miller DG, Ansari I, Sivalingam A. Intravitreal triamcinolone injection for the treatment of macular edema secondary to branch retinal vein occlusion. *Retina Congress* 2002.
16. Nelson ML, Martidis A, Miller DG, Spinak DJ, Federman JL. Intravitreal triamcinolone acetate injection for refractory pseudophakic cystoid macular edema. *Retina Congress* 2002.
17. Tennant MT, Nelson ML, Martidis A, Schuler MF, Blade KA, Federman JL, Benson WE. The incidence of persistent shallow subfoveal fluid in eyes that have undergone rhegmatogenous retinal detachment repair. *Retina Congress* 2002.
18. Nelson ML, Tennant MT, Belmont JB, Martidis A, Blade K, Sivalingam A. Clinical findings that differentiate pseudoendophthalmitis from bacterial endophthalmitis after injection of intravitreal triamcinolone acetate. *Retina Congress* 2002.
19. Borillo JL, Sivalingam A, Martidis A, Federman JL. Surgical ablation of retinal angiomatous proliferation in patients with exudative age-related macular degeneration. *Retina Congress* 2002.
20. Borillo JL, Sivalingam A, Martidis A, Federman JL. Surgical ablation of retinal angiomatous proliferation. *Club Jules Gonin* 2002.
21. Spinak DJ, Martidis A, Belmont JB, Miller DG. Intravitreal triamcinolone for pseudophakic cystoid macular edema. *American Academy of Ophthalmology* 2002.
22. Ansari I, Martidis A, Nelson ML, Belmont JB. Intravitreal triamcinolone for macular edema following branch retinal vein occlusion. *American Academy of Ophthalmology* 2002.
23. Nelson ML, Martidis A, Spinak DJ, Liu M, Sivalingam A, Federman JL. Intravitreal triamcinolone for refractory pseudophakic cystoid macular edema. *Invest Ophthalmol Vis Sci* 2003.
24. Garg SJ, Sivalingam A, Martidis A, Federman J. Six month follow-up of surgical ablation for stage 2 retinal angiomatous proliferation. *Invest Ophthalmol Vis Sci* 2003.
25. Chieh JJ, Liu M, Martidis A, Roth DB, Belmont J, Nelson M, Regillo C, Sivalingam A, Federman J. Intravitreal triamcinolone acetate for diabetic macular edema. *Invest Ophthalmol Vis Sci* 2003.

Adam Martidis, M.D.

26. Liu M, Martidis A, Roth D, Belmont J, Nelson M, Chieh J, Sivalingam A, Regillo C, Federman J. Complications of intravitreal triamcinolone acetonide. *Invest Ophthalmol Vis Sci* 2003.
27. Martidis A, Tennant MT, Federman JL. Triamcinolone-assisted membrane peeling in diabetic retinopathy and proliferative vitreoretinopathy. *American Society of Retina Specialists* 2003.
28. Garg SJ, Sivalingam A, Martidis A, Federman JL, Sarin LK. Intravitreal triamcinolone as primary treatment for clinically significant diabetic macular edema. *American Society of Retina Specialists* 2003.
29. Weichel ED. Martidis A, Fineman MS, McNamara JA, Park CH, Vander JF, Ho AC, Brown GC. Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachment., *Association for Research in Vision & Ophthalmology* 2004.
30. Weichel ED. Martidis A, Fineman MS, McNamara JA, Park CH, Vander JF, Ho AC, Brown GC. Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachment., *American Society of Retinal Specialists* 2004.
31. Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, Fontanarosa J, Moster MR. Intraocular pressure alterations following intravitreal triamcinolone acetonide. *American Academy of Ophthalmology* 2004.
32. Weichel ED. Martidis A, Fineman MS, McNamara JA, Park CH, Vander JF, Ho AC, Brown GC. Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachment., *Retina Society* 2005.
33. Weichel ED. Martidis A, Fineman MS, McNamara JA, Park CH, Vander JF, Ho AC, Brown GC. Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachment. *American Academy of Ophthalmology* 2005.
34. Martidis A, Chang TS, Win PH. Intravitreal bevacizumab versus ranibizumab for treatment-naïve neovascular age-related macular degeneration: a case control study. *American Society of Retina Specialists* 2007
35. Chang TS, Martidis A. Supra-choroidal drug delivery. *American Society of Retina Specialists* 2007

Book

- Puliafito CA, Rogers A, Martidis A, Greenberg PB. Ocular Photodynamic Therapy. Thorofare, NJ: Slack, Inc. 2002.

Book Chapters

1. Martidis A, Vitreoretinal Surgery. In Retina and Vitreous; Basic and Clinical Science Course. American Academy of Ophthalmology. Chicago, IL 2012.

Adam Martidis, M.D.

2. Martidis A, Focal and Diffuse Choroidal and Retinal Inflammation. In Retina and Vitreous; Basic and Clinical Science Course. American Academy of Ophthalmology. Chicago, IL 2012.
3. Martidis A, Tennant M, Bressler N. Age-related macular degeneration. In Yanoff M & Duker J (eds), Ophthalmology. Philadelphia, PA: Lippincott 2003.
4. Martidis A, Lane RG, Puliafito CA. Optical coherence tomography. In Ciulla TA, Harris A, & Regillo C (eds), Retinal and Optic Nerve Imaging. Philadelphia, PA. Lippincott 2003.
5. Rogers A, Martidis, A, Reichel E. Transpupillary thermotherapy of age-related macular degeneration. In Lim J (ed), Age-related Macular Degeneration. New York: Marcel Dekker, Inc, 2002.
6. Rivellesse M, Martidis A, Reichel E. Optical coherence tomography of age-related macular degeneration. In Lim J (ed), Age-related Macular Degeneration. New York: Marcel Dekker, Inc, 2002.